January - March 2026
- Net sales increased by 12% (29%) to SEK 270 million (242).
- Operating profit (EBIT) was SEK 5.2 million (5.5), corresponding to an EBIT margin of 1.9% (2.3%).
- Earnings per share before dilution were SEK 0.27 (0.31).
- Cash flow from operating activities was SEK 35.3 million (16.7).
- Cash flow for the period was SEK 26.4 million (12.9).
- Cash and cash equivalents totaled SEK 71.5 million at the end of the period.
Björn Thorngren, CEO, comments:
"The first quarter of 2026 demonstrates strong continued growth, particularly in prescription medicines, and improved profitability compared to Q4. We are gaining market share and growing our customer base."
"The trend is clear and stable - more and more Swedes are choosing to have their medication delivered at home rather than visiting a physical pharmacy."
"Work on our new logistics center is progressing according to plan. The facility nearly triples our warehouse space and gives us capacity to grow for a long time to come. We are also investing in further strengthened automation capacity within packing and order sorting."
The results for the period January - March 2026 will be presented by MEDS CEO Björn Thorngren and CFO Nick Mendola today at 09:30 CEST. The presentation will be held in English. Please contact ir@meds.se to receive a link to the presentation (at latest 09:00 CEST today).
For further information, please contact:
Press contact, email: press@meds.se
IR contact, email: ir@meds.se
About MEDS
MEDS, launched in 2018, is a full-scale online pharmacy licensed by the Swedish Medical Products Agency, operating in the Swedish market. MEDS offers customers prescription medicines, over-the-counter medicines, and a wide range of pharmacy-related products. As of March 31, 2026, the company had more than 1 million active customers. Net sales for the past twelve months, as of March 31, 2026, amounted to approximately SEK 1 034 million. The company's headquarters are in Stockholm, and as of March 31, 2026, the number of FTE employees was 49.
This information is information that MEDS Apotek AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-05-05 07:30 CEST.
